Thank you for a great walk and all your support 5/5/18!
from the daughters of Robert Miningham and Dr. Phillips and Dr.Konno.
More walks to be announced
Join Our Fundraising-
Seize the Ribbon Foundation for Bladder Cancer Research was founded in 2010 by the Miningham Family.
The foundation supports the work of
Drs. John Phillips and Senuki Konno at New York Medical College supporting innovative and progressive treatment of Bladder Cancer with research work in both molecular and herbal approaches to bladder cancer treatments.
Over 81,000 will be diagnosed with bladder cancer in a year-
-It is the eighth most common cause of cancer deaths-
Men are 4 times as likely to be diagnosed than females!
Signs-Blood in the urine, Painful urination, Urgent need to urinate, Feeling the need but not able to urinate
Symptoms-Abdominal pain, Fatigue, Lower back pain, Appetite or weight loss
Risk Factors-Smoking, Race, gender and age, Medical history of cancer, Chronic bladder inflammation
*5 year survival rate tells you what percent of people live at least 5 years after cancer is found. Bladder cancer has a 77% rate.
So catch it now!
Seize The Ribbon has two doctors working to find bladder cancer destroying answers at New York Medical College in Valhalla, NY.
New York Medical College is the leading academic biomedical research center between New York City and the New York state capital of Albany. The College manages research and other sponsored programs, notably in the areas of cancer, cardiovascular disease, infectious diseases, kidney disease, the neurosciences, disaster medicine, and vaccine development.
|File Size:||558 kb|
Dr. John Phillips
Extracts of maitake mushrooms called the maitake D-fraction (PDF) appear to synergize with vitamin C (VC) in producing an anti-tumor effect. We are currently determining whether there is a tissue- and dose-specific effect of the PDF/VC combination in a controlled murine model. A Phase III trial is being established to determine whether PDF/VC decreases the recurrence and/or progression rate of superficial bladder cancers. The target of PDF/VC appears to be cell cycle regulatory proteins, p21 and p53. We aim to determine whether tumor expression of these two molecules, or the expression of Fibroblast Growth Factor Receptor-III (FGFR-III) predicts responsiveness to PDF/VC.